Treatment of severe acute respiratory syndrome

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 9, 2005, Pages 583-591

  Lai, S T ^a  

^a PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA INTERFERON; CEPHALOSPORIN; CORTICOSTEROID; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERFERON; LOPINAVIR; MEPREDNISONE; PREDNISONE; QUINOLONE; RIBAVIRIN; RITONAVIR;

AIR CONDITIONING; ANEMIA; ARTHRALGIA; BACTEREMIA; BRADYCARDIA; CHINESE MEDICINE; CONVALESCENCE; DIARRHEA; DRUG POTENCY; DRUG SAFETY; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOXIA; NONHUMAN; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; THORAX RADIOGRAPHY; URINARY TRACT INFECTION; VIRUS INFECTION;

ADRENAL CORTEX HORMONES; ANTIVIRAL AGENTS; CLINICAL PROTOCOLS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MEDICINE, CHINESE TRADITIONAL; PLASMA EXCHANGE; POSITIVE-PRESSURE RESPIRATION; RESPIRATION, ARTIFICIAL; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 26844456603     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-0004-z     Document Type: Review

References (108)

1. Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, Nicholls J, Yee WKS, Yan WW, Cheung MT, Cheng VCC, Chan KH, Tsang DNC, Yung RWH, Ng TK, Yuen KY, SARS Study Group (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319-1325
2. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ, sSARS Working Group (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348:1953-1966
3. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A, Burguiere AM, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348:1967-1976
4. World Health Organization (2004) Cumulative number of reported probable cases, http://www.who.int/csr/sars/country/table2004_04_21/en/. Cited 16 February 2005
5. Falsey AR, Walsh EE (2003) Novel coronavirus and severe acute respiratory syndrome. Lancet 361:1312-1313
6. Shi J, Wei Z, Song J (2004) Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors. J Biol Chem 279:24765-24773
7. Liu Z, Huang C, Fan K, Wei P, Chen H, Liu S, Pei J, Shi L, Li B, Yang K, Liu Y, Lai L (2005) Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase. J Chem Inf Model 45:10-17
8. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, Tolley EA (1998) Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 280:159-165
9. Epler GR (2001) Bronchiolitis obliterans organizing pneumonia. Arch Intern Med 161:158-164
10. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, Volk HD, Doecke WD, Falke KJ, Gerlach H (2003) Immunologic and hemodynamic effects of "low dose" hydrocortisone in septic shock. Am J Resp Crit Care Med 167:512-520
11. Tsang OTY, Chau TN, Choi KW, Tso EYK, Lim W, Chiu MC, Tong WL, Lee PO, Lam BHS, Ng TK, Lai JY, Yu WC, Lai ST (2003) Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 9:1381-1387
12. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, Kao RYT, Poon LLM, Wong CLP, Guan Y, Peiris JSM, Yuen KY, on behalf of the HKU/UCH SARS Study Group (2004) Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59:252-256
13. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK (1972) Broad-spectrum antiviral activity of virazole: 1-beta-D-ribofuranosyl-1, 2,4-triazole-3-carboxamide. Science 177:705-706
14. Cameron CE, Castro C (2001) The mechanism of action of ribavirin: lethal mutagenesis of RNA virus mediated by the viral RNA-dependent RNA polymerase. Curr Opin Infect Dis 12:261-272
15. Huggins JW (2003) Severe acute respiratory syndrome (SARS) and coronavirus testing - United States. Morb Mortal Wkly Rep 52:297-302
16. Health Canada (2003) Management of severe acute respiratory syndrome (SARS) in adults: interim guidance for health pro viders. http://www.hc.sc.gc. ca/. Cited 16 February 2005
17. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW (2003) Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 3361:2045-2046
18. Leong HN, Ang B, Earnest A, Teoh C, Xu W, Leo YS (2004) Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. Trop Med Int Health 9:923-927
19. Stroher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, Jones SM, Feldmann H (2004) Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis 189:1164-1167
20. Booth CM, Matukas LM, Tomlinsom GA, Rachlis AR, Rose DB, Dwosh HA, Walmsley SL, Mazzulli T, Avendano M, Derkach P, Ephtimios IE, Kitai I, Mederski BD, Shadowitz SB, Gold WL, Hawryluck LA, Rea E, Chenkin JS (2003) Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289:2801-2809
21. Choi KW, Chau TN, Tsang O, Tso E, Chiu MC, Tong WL, Lee PO, Ng TK, Ng WF, Lee KC, Lam W, Yu WC, Lai JY, Lai ST, Princess Margaret Hospital SARS Study Group (2003) Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med 139:715-723
22. Cyranoski D (2003) Critics slam treatment for SARS as ineffective and perhaps dangerous. Nature 423:4
23. Wenzel RP, Edmond MB (2003) Managing SARS amidst uncertainty. N Engl J Med 348:1947-1948
24. Knowles SR, Phillips EJ, Dresser L, Matukas L (2003) Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome. Clin Infect Dis 37:1139-1142
25. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY, HKU/UCH SARS Study Group (2003) Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361:1767-1772
26. van Vonderen MGA, Bos JC, Prins JM, Wertheim-van Dillen P, Speelman P (2003) Ribavirin in the treatment of severe acute respiratory syndrome (SARS). Neth J Med 61:238-241
27. Zhaori G (2003) Antiviral treatment for SARS: can we draw any conclusion? Can Med Assoc J 169:1165-1166
28. Hurst M, Faulds D (2000) Lopinavir. Drugs 60:1371-1379
29. Cvetkovic RS, Goa KL (2003) Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 63:769-802
30. Leung WK, To KF, Chan PKS, Chan HL, Wu AK, Lee N, Yuen KY, Sung JJ (2003) Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 125:1011-1017
31. Kwan ACP, Chau TN, Tong WL, Tsang OTY, Tso EYK, Chiu MC, Yu WC, Lai TST (2005) Severe acute respiratory syndrome (SARS) related diarrhoea. J Gastroenterol Hepatol 20:606-610
32. Lee PO, Tsui PT, Tsang TY, Chau TN, Kwan CP, Yu WC, Lai ST, Princess Margaret Hospital SARS Study Group (2005) Severe acute respiratory syndrome: clinical features. In: Schmidt A, Wolff MH, Weber O (eds) Coronaviruses with special emphasis on first insights concerning SARS. Birkhäuser Verlag, Basel, pp 71-85
33. Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MM, Tse MW, Que TL, Peiris JS, Sung J, Wong VC, Yuen KY (2003) Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 9:399-406
34. Lee N, Sung J (2003) The use of corticosteroids in SARS. N Engl J Med 348:2034-2035
35. Van Reeth K, Van Gucht S, Pensaert M (2002) Correlations between lung proinflammatory cytokine levels, virus replication, and disease after swine influenza challenge of vaccination-immune pigs. Viral Immunol 15:583-594
36. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, Gordon S, Guan Y, Peiris JS (2002) Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 360:1831-1837
37. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ (2004) Plasma inflammatory cytokines in severe acute respiratory syndrome. Clin Exp Immunol 136:95-103
38. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, Chu CM, Hui PK, Mak KL, Lim W, Yan KW, Chan KH, Tsang NC, Guan Y, Yuen KY, Peiris JS (2003) Lung pathology of fatal severe acute respiratory syndrome. Lancet 361:1773-1778
39. Franks TJ, Chong PY, Chui P, Galvin JR, Lourens RM, Reid AH, Selbs E, McEvoy CP, Hayden CD, Fukuoka J, Taubenberger JK, Travis WD (2003) Lung pathology in severe acute respiratory syndrome (SARS): a study of 8 autopsy cases in Singapore. Hum Pathol 34:743-748
40. Tse GM, To KF, Chan PK, Lo AW, Ng KC, Wu A, Lee N, Wong HC, Mak SM, Chan KF, Hui DS, Sung JJ, Ng HK (2004) Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 57:260-265
41. Fishman DN (2000) Hemophagocytic syndrome and infection. Emerg Infect Dis 6:60-68
42. Lai KN, Leung JC, Metz CN, Lai FM, Bucala R, Lan HY (2003) Role for macrophage migration inhibitory factor in acute respiratory distress syndrome. J Pathol 199:496-508
43. Wong KT, Antonio GE, Hui DS, Lee N, Yuen EH, Wu A, Leung CB, Rainer TH, Cameron P, Chung SS, Sung JJ, Ahuja AT (2003) Thin scan CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. Radiology 228:395-400
44. Yao W, Chen Y, Zhang L, Wang X, Sun Y, Sun W, Han J, Zhang F, Zheng Y, Sun B, He B, Zhao M (2004) Chest X-ray changes in severe acute respiratory syndrome cases after discontinuation of glucocorticosteroids treatment. Chin Med J 117:143-144
45. Lee N, Chan KC, Hui DS, Ng EK, Wu A, Chiu RW, Wong VW, Chan PK, Wong KT, Wong E, Cockram CS, Tam JS, Sung JJ, Lo YM (2004) Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol 31:304-309
46. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, Lam WK, Seto WH, Yam LY, Cheung TM, Wong PC, Lam B, Ip MS, Chan J, Yuen KY, Lai KN (2003) A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348:1977-1985
47. Lee N, Hui DS, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY, Leung CB, To KF, Lui SF, Szeto CC, Chung S, Sung JJ (2003) A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348:1986-1994
48. Tsui PT, Kwok ML, Yuen H, Lai ST (2003) Severe acute respiratory syndrome: clinical outcomes and prognostic correlates. Emerg Infect Dis 9:1064-1069
49. So LK, Lau AC, Yam LY, Cheung TM, Poon E, Yung RW, Yuen KY (2003) Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 361:1615-1617
50. Chan JWM, Ng KC, Chan YH, Mok TYW, WHO, Lee S, Chu SYY, Law WL, Lee MP, Li PCK (2003) Short-term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 58:686-689
51. Sung JJY, Wu A, Joynt GM, Yuen KY, Lee N, Chan PKS, Cockram CS, Ahuja AT, Yu LM, Wong VW, Hui DSC (2003) Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 59:414-420
52. Tsang KW, Lam WK (2003) Management of severe acute respiratory syndrome - the Hong Kong University experience. Am J Resp Crit Care Med 168:417-424
53. Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, Wong PC, Li PC, Ho PL, Lam WK, Ng KC, Ip MS, Lai KN, Chan-Yeung M, Tsang KW (2003) High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Resp Crit Care Med 168:1449-1456
54. Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, Xiong J, Hawkey PM (2003) Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 52:715-720
55. Wu W, Wang J, Liu P, Chen W, Yin S, Jiang S, Yan L, Zhan J, Chen X, Li J, Huang Z, Huang H (2003) A hospital outbreak of severe acute respiratory syndrome in Guangzhou, China. Chin Med J 116:811-818
56. Zheng ZG, Zhong NS (2003) The use of corticosteroids in management of critical SARS. Chin Med J 42:676-677
57. Zhong NS, Zeng GQ (2003) Our strategies for fighting severe acute respiratory syndrome (SARS). Am J Resp Crit Care Med 168:7-9
58. Li N, Ma J, Nie L, Li H, Que C, Gao Z, Wang G, Xu X, Lu H, Wang G (2003) Retrospective analysis of the corticosteroids treatment on severe acute respiratory syndrome (SARS) Beijing Daxue Xuebao 35(Suppl):16-18
59. Sun H-Y, Fang C-T, Wang J-T, Chen Y-C, Chang S-C (2003) Treatment of severe acute respiratory syndrome in health-care workers. Lancet 362:2025-2026
60. Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W (2003) Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 349:507-508
61. Hong N, Du XK (2004) Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol 59:602-608
62. Chan CW, Chiu WK, Chan CC, Chow EY, Cheung HM, Ip PL (2004) Osteonecrosis in children with severe acute respiratory syndrome. Pediatr Infect Dis J 23:888-890
63. Griffith JF, Antonio GE, Kumta SM, Hui DSC, Wong JKT, Joynt GM, Wu AKL, Cheung AY, Chiu KH, Chan KM, Leung PC, Ahuja AT (2005) Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 235:168-175
64. Wong VW, Dai D, Wu AK, Sung JJ (2003) Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 9:199-201
65. Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, Ng MH, Chan P, Cheng G, Sung JJ (2004) Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infection 10:676-678
66. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G (2005) Use of convalescent plasma in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24:44-46
67. Ali MB (2003) Treating severe acute respiratory syndrome with hyperimmune globulins. Hong Kong Med J 9:391-392
68. Chiang CH, Chen HM, Shih JF, Su WJ, Perng RP (2003) Management of hospital-acquired severe acute respiratory syndrome with different disease spectrum. J Chin Med Assoc 66:328-338
69. Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K, Kwan KM, Chan Y, Yim CF, Bek SL, Kor AC, Yap WS, Chelliah YR, Lai YC, Goh SK (2003) Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 290:374-380
70. Ho JC, Wu AY, Lam B, Ooi GC, Khong PL, Ho PL, Chan-Yeung M, Zhong NS, Ko C, Lam WK, Tsang KW (2004) Pentaglobin in steroid-resistant severe acute respiratory syndrome. Int J Tuberc Lung Dis 8:1173-1179
71. Confalonieri M, Potena A, Carbone G, Porta RD, Tolley EA, Umberto Meduri G (1999) Acute respiratory failure in patients with severe community-acquired pneumonia. Am J Resp Crit Care Med 160:1585-1591
72. Luo D, Qian SC (2003) SARS treatment: experience from a team in Guangdong, China. Chin Med J 116:838-839
73. Yam LYC, Chen RC, Zhong NS (2003) SARS: ventilatory and intensive care. Respirology 8(Suppl):S31-S35
74. Cheung TMT, Yam LYC, So LKY, Lau ACW, Poon E, Kong BMH, Yung RWH (2004) Effectiveness of noninvasive positive pressure ventilation in the treatment of acute respiratory failure in severe acute respiratory syndrome. Chest 126:845-850
75. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW (2003) Treatment of SARS with human interferons. Lancet 362:748
76. Tan EL, Ooi EE, Lin CY, Tan HC, Ling AE, Lim B, Stanton LW (2004) Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 10:581-586
77. Hensley LE, Fritz EA, Jahrling PB, Karp CL, Huggins JW, Geisbert TW (2004) Interferon-β1a and SARS coronavirus replication. Emerg Infect Dis 10:317-319
78. Sainz B Jr, Mossel EC, Peters CJ, Garry RF (2004) Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 329:11-17
79. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr (2005) Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 326:905-908
80. Zheng B, He ML, Wong KL, Lum CT, Poon LL, Peng Y, Guan Y, Lin MC, Kung HF (2004) Potent inhibition of SARS-associated coronavirus (SCoV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma). J Interferon Cytokine Res 24:388-390
81. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Pham DH, Deif H, LaMere EA, Chang M, Kain KC, Farcas GA, Ferguson P, Latchford M, Levy G, Dennis JW, Lai EK, Fish EN (2003) Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290:3222-3228
82. Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Amerongen G, van Riel D, de Jong T, Itamura S, Chan KH, Tashiro M, Osterhaus AD (2004) Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 10:290-293
83. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450-454
84. Chiu RW, Tang NL, Hui DS, Chung GT, Chim SS, Chan KC, Sung YM, Chan LY, Tong YK, Lee WS, Chan PK, Lo YM (2004) ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. Clin Chem 50:1683-1686
85. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA (2004) Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 101:2536-2541
86. Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, Fan KW, Cheng VC, Tsui WH, Hung IF, Lee TS, Guan Y, Peiris JS, Yuen KY (2004) In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 31:69-75
87. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, Rabenau H, Doerr HW, Hunsmann G, Otaka A, Tamamura H, Fujii N, Yamamoto N (2004) HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 318:719-725
88. He ML, Zheng B, Peng Y, Peiris JS, Poon LL, Yuen KY, Lin MC, Kung HF, Guan Y (2003) Inhibition of SARS-associated coronavirus infection and replication by RNA interference. JAMA 290:2665-2666
89. Kao RY, Tsui WHW, Lee TSW, Tanner JA, Watt RM, Huang J-D, Hu L, Chen G, Chen Z, Zhang L, He T, Chan K-H, Tse H, To APC, Ng LWY, Wong BCW, Tsoi H-W, Yang D, Ho DD, Yuen K-Y (2004) Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem Biol 11:1293-1299
90. Zhang XW, Yap YL (2004) Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design. Bioorg Med Chem 12:2219-2223
91. Zhang XW, Yap YL (2004) Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg Med Chem 12:2517-2521
92. Chen XP, Cao Y (2004) Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome. Clin Infect Dis 38:1030-1032
93. Tobinick E (2004) TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection. Curr Med Res Opin 20:39-40
94. Keyaerts E, Vijgen L, Chen L, Maes P, Hedenstierna G, Van Ranst M (2004) Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N- acetylpenicillamine, a nitric oxide donor compound. Int J Infect Dis 8:223-226
95. Akerstrom S, Mousavi-Jazi M, Klingstrom J, Leijon M, Lundkvist A, Mirazimi A (2005) Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol 79:1966-1969
96. Kontoyiannis DP, Pasqualini R, Arap W (2003) Aminopeptidase N inhibitors and SARS. Lancet 361:1558
97. Lin L, Han Y, Yang ZM (2003) Clinical observation on 103 patients of severe acute respiratory syndrome treated by integrative traditional Chinese and Western medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi 23:409-413
98. Zhang RL, Jiao Q, Wang BG (2003) Controlled clinical study on 49 patients of SARS treated by integrative Chinese and Western medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi 23:654-657
99. Li J, Li SD, Du N (2004) Clinical study on treatment of severe acute respiratory syndrome with integrative Chinese and Western medicine approach. Zhongguo Zhong Xi Yi Jie He Za Zhi 24:28-31
100. Chen Z, Nakamura T (2004) Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS. Phytother Res 18:592-594
101. Lau AC, So LK, Miu FP, Yung RW, Poon E, Cheung TM, Yam LY (2004) Outcome of coronavirus-associated severe acute respiratory syndrome using a standard treatment protocol. Respirology 9:173-183
102. Hong Kong Hospital Authority (2004) Treatment guidelines for adult patients with SARS. Updated 11 February 2004. http://ha.home/ho/pa/ UpdatedTreatmentGuidelines040416.doc. Cited 16 February 2005
103. World Health Organization (2004) WHO guidelines for the global surveillance of severe acute respiratory syndrome (SARS). Updated recommendations, October 2004. http://www.who.int/csr/resources/publications/en/ WHO_CDS_CSR_ARO_2004_1.pdf. Cited 16 February 2005
104. Tsang KW, Zhong NS (2003) SARS: pharmacotherapy. Respirology 8(Suppl):S25-S30
105. Zhong N, Ding Y, Mao Y, Wang Q, Wang G, Wang D, Cong Y, Li Q, Liu Y, Ruan L, Chen B, Du X, Yang Y, Zhang Z, Zhang X, Lin J, Zheng J, Zhu Q, Ni D, Xi X, Zeng G, Ma D, Wang C, Wang W, Wang B, Wang J, Liu D, Li X, Liu X, Chen J, Chen R, Min F, Yang P, Zhang Y, Luo H, Lang Z, Hu Y, Ni A, Cao W, Lei J, Wang S, Wang Y, Tong X, Liu W, Zhu M, Zhang Y, Zhang Z, Zhang X, Li X, Chen W, Xhen X, Lin L, Luo Y, Zhong J, Weng W, Peng S, Pan Z, Wang Y. Wang R, Zuo J, Liu B, Zhang N, Zhang J, Zhang B, Zhang Z, Wang W, Chen L, Zhou P, Luo Y, Jiang L, Chao E, Guo L, Tan X, Pan J, Chinese Medical Association, China Association of Chinese Medicine (2003) Consensus for the management of severe acute respiratory syndrome. Chin Med J 116:1603-1635
106. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, Tellier R, Draker R, Adachi D, Ayers M, Chan AK, Skowronski DM, Salit I, Simor AE, Slutsky AS, Doyle PW, Krajden M, Petric M, Brunham RC, McGeer AJ, Canadian Severe Acute Respiratory Syndrome Study Team (2003) Identification of severe acute respiratory syndrome in Canada. N Engl J Med 348:1995-2005
107. Hsu LY, Lee CC, Green JA, Ang B, Paton NI, Lee L, Villacian JS, Lim PL, Earnest A, Leo YS (2003) Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 9:713-717
108. Anonymous (2003) Update: severe acute respiratory syndrome - United States, 2003. MMWR Morb Mortal Wkly Rep 52:616